The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

heartseed.jp

Total Raised

$70.18M

Investors Count

16

Deal Terms

1

Heartseed Funding, Heartseed Valuation & Heartseed Revenue

4 Fundings

Heartseed's latest funding round was a Series C for $37M on June 11, 2021.

Heartseed's valuation in July 2018 was $19.53M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/11/2021

Series C

$37M

0

FY undefined

13

3/10/2020

Series B - II

0

FY undefined

10

11/22/2019

Series B

$99M

0

FY undefined

10

7/30/2018

Series A

$99M

$19.53M

0

FY undefined

10

Date

6/11/2021

3/10/2020

11/22/2019

7/30/2018

Round

Series C

Series B - II

Series B

Series A

Amount

$37M

$99M

$99M

Investors

Valuation

$19.53M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

13

10

10

10

Heartseed Deal Terms

1 Deal Term

Heartseed's deal structure is available for 1 funding round, including their Series A from July 30, 2018.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

Heartseed Investors

16 Investors

Heartseed has 16 investors. Nissay Capital invested in Heartseed's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/22/2019

6/11/2021

2
Series B, Series C (2021)

Corporate Venture

Japan

3/10/2020

6/11/2021

2
Series B - II, Series C (2021)

Corporation

Japan

3/10/2020

6/11/2021

2
Series B - II, Series C (2021)

Holding Company

Japan

00/00/0000

00/00/0000

UTokyo Innovation Platform

Subscribe to see more

Corporate Venture

Japan

00/00/0000

00/00/0000

Medical Incubator Japan

Subscribe to see more

Incubator/Accelerator

Japan

First funding

11/22/2019

3/10/2020

3/10/2020

00/00/0000

00/00/0000

Last Funding

6/11/2021

6/11/2021

6/11/2021

00/00/0000

00/00/0000

Investor

UTokyo Innovation Platform

Medical Incubator Japan

Rounds

2
Series B, Series C (2021)
2
Series B - II, Series C (2021)
2
Series B - II, Series C (2021)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporate Venture

Corporation

Holding Company

Corporate Venture

Incubator/Accelerator

Location

Japan

Japan

Japan

Japan

Japan

You May Also Like

A
Avery Therapeutics

Avery Therapeutics is a company that focuses on developing tissue-engineered therapeutics to treat diseases and injuries to human muscles. Its main product, MyCardia, is being developed to address and treat heart failure. It specializes in tissue engineering therapeutics, tissue engineering, regenerative medicine, cardiology, and more. It was founded in 2016 and is based in Tucson, Arizona.

C
CUORiPS

CUORiPS is a developer of cell therapy products. The company develops allogeneic iPSC-derived cardiomyocyte sheets for the treatment of heart failure. It aims to enable transplantation of the sheets for patients with severe deficiencies in their heart function.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.